Catalent Pharma Solutions has finished renovating its 3,300 square foot aseptic fill-finish manufacturing facility in North Carolina. The renovation ties into Catalent's plan to boost its offerings in areas like advanced blow-fill-seal aseptic delivery, delivery technologies and clinical trial supplies, among others.
The clinical manufacturing suite will provide Class A manufacturing space containing a flexible aseptic vial-filling line capable of producing Phase I and Phase II clinical trial materials, the company said in a statement. The renovation should provide a "fourfold increase" of the sterile fill-finish capacity at the facility.
"It is part of Catalent's ongoing investment to provide integrated solutions to meet biologic and biosimilar drug development companies' growing needs," says Christine Dolan, vice president and general manager of Catalent's development and analytical solutions business, in a statement.
Dolan also tells Outsourcing-Pharma that the renovated plant is meant to increase capacity and build upon Catalent's "existing expertise and offerings" as a direct response to customer feedback. It is part of Catalent's plan to focus more on expanding its work in biologics, Dolan added. Toward that end, the comany recently announced the sale of its U.S. commercial packaging operations in Philadelphia, and Woodstock, IL. Venture capital group Frazier Healthcare purchased the ops for an undisclosed sum.
- learn more from Outsourcing-Pharma
- read Catalent's statement